Candriam strengthens biotech fund team

Servaas MichielssensCandriam Investors has expanded its Brussels-based biotech equity strategy team, with the appointment of Servaas Michielssens as senior biotechnology analyst. He will be charged with assessing the latest drug development trends for the €440 million Candriam Equities L Biotechnology fund. Since launch, the fund has produced an average annual return of 24.6%, although is down 17.9% year-to-date. Michielssens joins from the Max Planck Institute in Germany, where he has spent two years developing computational protocols serving research of biomolecules with improved properties. He holds a Masters in computational chemistry and a PhD in science from the University of Leuven in Belgium. A spokesperson said the firm was attracted to Michielssens’ extensive knowledge of small molecule drug development, and believe it will complement the team’s current protein drug specialism. Candriam manages assets of €94.1 billion and last month reported inflows of €1 billion a month for 2015. ©2016 funds europe

Executive Interviews

INTERVIEW: Put your money where your mouth is

Jun 10, 2016

At Kempen Capital Management, they believe portfolio managers should invest in their own funds. David Stevenson talks to Lars Dijkstra, CIO of the €42 billion manager.

EXECUTIVE INTERVIEW: ‘Volatility is the name of the game’

May 13, 2016

Axa Investment Managers chief executive officer, Andrea Rossi, talks to David Stevenson about bringing all his firm’s subsidiaries under one name and the opportunities that a difficult market...


ROUNDTABLE: Beyond the hype

Oct 13, 2016

The use of smart beta investing continues to grow. Our panel, made up of both providers and users, discusses what the strategy actually means, how it should be used and the kind of pitfalls that may arise when using this innovative investment technique.

MIFID II ROUNDTABLE: Following the direction of travel

Sep 07, 2016

Fund management firms Aberdeen and HSBC Global meet with specialist providers to speak about how the industry is evolving towards MiFID II.